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Preterm delivery is associated with disruption of the placental supply with 17β-estradiol (E2) and progesterone (P). The aim is to
evaluate the role of E2 and P on the regulation of key proteins in lung development in embryonic lung cells. Alveolar cell type II
(AT-II) and central lung ﬁbroblast cultures were established from mouse embryos. Cells were exposed for 24hours to E2 and/or P,
the estrogen receptor antagonist ICI 182,780 (ICI) and the progesterone receptor antagonist mifepristone (RU 486). The mRNA
expression of vascular endothelial growth factor (VEGF) and surfactant protein B and C (SB-B, SB-C) was determined and protein
levels of VEGF were measured. Only the combined treatment with E2 and P increased mRNA expression and VEGF protein in
AT-II cells and lung ﬁbroblasts. Combined treatment also promoted SP-B and SP-C expression in AT-II cells. Pretreatment with
ICI and RU 486 completely abolished the E2 and P induced eﬀects. E2 and P enhanced expression of VEGF and surfactant proteins
in primary embryonic lung cells and may be involved in regulating expression of key molecules for the prenatal lung development
and postnatal lung function.
Copyright © 2009 Andreas Trotter et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Respiratory distress syndrome (RDS) and bronchopul-
monary dysplasia (BPD) remain major factors for morbidity
and mortality in extremely preterm infants. Histopathologi-
cal studies in preterm infants dying from BPD demonstrate
an arrest of lung development with reduced alveologenesis
[1]. The concept has evolved that postnatal lung develop-
ment in extremely preterm infants is arrested by lack of
factors that regulate lung diﬀerentiation and maturation
in utero [2]. During mid and late gestation, the human
fetus is exposed to high amounts of 17β-estradiol (E2)
and progesterone (P) [3] produced by the placenta from
precursors originating from the mother and the fetus [4].
Delivery disrupts the placental supply of both hormones.
Within one day, the levels of E2 and P drop 100-fold [5].
This is a physiologic condition for the term infant. The
extremely preterm infant is disrupted from the supply of
these hormones at a much earlier developmental stage. The
uterus as a known estrogen responsive target grows in utero
until the end of gestation but stops growing in preterm
infants [6]. It is conceivable that the withdrawal of E2
and P at this early developmental stage also aﬀects lung
development. Replacement of E2 and P in extremely preterm
infants tailored to maintain in utero plasma levels of E2 and
P was associated with a trend toward a reduced incidence of
BPD [5, 7].
In mice lung mRNA expression of estrogen and pro-
gesterone receptors suggests that E2 and P are likely to be
involved in mammalian fetal lung development [8]. The
number of alveolar crests and alveolar type II cells [9]a sw e l l
as lamellar bodies in type II cells [10] increased in rat fetuses
after maternal E2 administration and E2 stimulates fetal
lung surfactant production in rabbits [11, 12]. In newborn
piglets antagonism of E2 and P during mid to late pregnancy
decreased alveolarization [13].2 International Journal of Pediatrics
Vascular endothelial growth factor (VEGF) is a major
mitogen for vasculogenesis and angiogenesis [14] and is
essential for embryonic development. Loss of a single VEGF
alleleresultsinembryoniclethality [15].Absenceof isoforms
ofVEGFimpairslungmicrovasculardevelopmentanddelays
airspace maturation in mice fetuses reﬂecting the essential
role of VEGF for normal lung development [16]. Pneu-
motrophic eﬀects may be mediated through modulation
of VEGF expression with the potential to accelerate lung
maturation in preterm infants [17]. Intra-amniotic injection
of VEGF in preterm rats resulted in increased surfactant pro-
tein B (SP-B) mRNA expression [18]. Type 2 pneumocytes
respond to VEGF by increasing their expression of SP-B and
SP-C [17].
Both sex steroids E2 and P and VEGF are described to
induce surfactant proteins in the developing lung. Whereas it
is established that E2 and P induce VEGF gene transcription
in breast tumor cell lines [19] and the endometrium [20–22]
no data from the literature is available about the eﬀects of E2
and P on VEGF gene transcription in lung tissue. The aim of
t h i ss t u d yw a st oi n v e s t i g a t ei fE 2a n dPa r ei n v o l v e di nt h e
developmental regulation of VEGF and surfactant protein B
(SB-B) and C (SB-C) mRNA expression using an in vitro
model of cultured embryonic lung cells.
2.MaterialandMethods
All experiments followed the local guidelines according to
the Federation of European Laboratory Animal Science
Associations recommendations and were approved by local
executives.
2.1. Cell Culturing and Treatment. Highly enriched alveolar
cell type II (AT-II) and central lung ﬁbroblast cultures were
established from embryonic day (ED) 18 BALB/c mice as
followed. Since E18 mouse lungs can be dissected from the
surrounding vessels in a reliable manner we did choose this
developmental stage to isolate puriﬁed AT-II cells from the
mouse lung. Brieﬂy, the fetuses were removed on ED 18 by
caesarian section and the lungs aseptically explanted from
the thorax. Lungs were then washed three times in 10mL
ice cold HBSS, mechanically dissected from surrounding
vessels, and then incubated in a 2.5% trypsin solution
containing 200μL of DNAse 1 (2mg/mL, Worthington)
for 10 minutes at 37◦C in a shaking water bath (60rpm).
Finally,the cellsuspensionwasﬁlteredthrougha nylonmesh
with 100-μm pore size. The cell suspension was centrifuged
twice at 420 and then 120g for 4 minutes, and the pellet
was resuspended in minimal essential medium (MEM).
The resulting cell suspension contained the AT-II cells
and attaching ﬁbroblasts. After adding 1.5ML collagenase
(1250U/mL, Worthington) and 150μL DNAse 1 (2mg/mL,
Worthington) the suspension was incubated for 15 minutes
at 37◦C. After stopping the collagenase activity by incubating
in ice-cold MEM (supplemented with 10% FCS) the cell
suspension was centrifuged as above for 4 minutes and the
pellet was resuspended in MEM + 10% FCS. Cells were
seeded and cultivated in a ﬁbronectin-coated culture ﬂask
for 1 hour at 37◦C under 5% CO2/21% O2. During this
time, ﬁbroblasts were attached to the ﬂask, while AT-II cells
did not due to their diﬀerential adherence characteristics.
This procedure was repeated twice. Finally, approximately
1 × 105 AT-II cells/cm2 were seeded at 24-well culture plates,
cultured for one day in MEM supplemented with 10% FCS.
Medium was changed after 24 hours to Cellgro complete
medium (Mediatech, Virginia, USA, without phenol red).
Attached ﬁbroblasts were resuspended by trypsination and
replated. When cells reached a conﬂuence of approximately
80% the medium was changed and the ﬁnal treatment was
started. Cells were exposed for 24 hours to E2 and/or P
and dexamethasone (all from Sigma-Aldrich, Germany) in
concentrations ranging from 10–10M to 10–6M. Pretreat-
ment with the estrogen receptor antagonist ICI 182,780
(TOCRIS bioscience, UK, 0.1μM) and the progesterone
receptor antagonist mifepristone (RU 486 from Biomol,
Germany, 0.1μM) was performed 1 hour before hormone
exposure. Concentrations of ICI and RU 468 were derived
by preparing a 10–2M stock solution in ethanol 100% p.a.
quality and by further diluting in medium. Appropriate
ethanol concentrations served as controls.
2.2. Gene Expression Analysis. The mRNA expression of
VEGF, SP-B, and SP-C was quantiﬁed using the rtPCR
technology (BioRad, Germany), QTM SYBR Green Super-
mix (BioRad, Germany), and a standardized protocol as
described previously [23, 24]. Isolation of total RNA was
performed with peq Gold (PeqLab, Germany). RNA con-
centration and purity were assessed using OD260 and
OD260/OD280 ratio, respectively, and reverse transcribed
using an Invitrogen M-MLV RT-kit and random hexanu-
cleotide primers. The rtPCR reactions were carried out in
a reaction mixture consisting of 2μL cDNA, 6μL RNAse-
free water, 10μL hot StartTaq DNA-polymerase, and 1μL
of primer (10pmol). Reactions were conducted in standard
tubes using the MyIQ rtPCR Detection System (BioRad,
Germany) under following conditions: 10-minute enzyme
activation at 95◦C, 45 cycles of 15-second denaturation at
95◦C, 30-second annealing at individual temperatures, 30-
second ampliﬁcation at 72◦C, and 5-second ﬂuorescence
measurement at 80◦C. Primer sequences to detect VEGF, SP-
B ,an dS P - Car es h o wni nTable 1.Relative quantiﬁcationwas
performed using the ΔCt method, which results in ratios
between target genes and a housekeeping reference gene
(HPRT). As the validity of this method critically depends on
the constant expression of the housekeeping gene, constant
expression of HPRT was tested against other housekeeping
genes (not shown). In each run, external standard curves
were generated by several fold dilutions of target genes. The
concentration of the target genes was calculated by compar-
ing Ct values in each sample with Ct values of the internal
standardcurve.Finally,datawereexpressedastheratioofthe
amountof eachtranscript versus the concentrationof HPRT.
Melting curves and gel electrophoresis of the PCR products
were routinely performed to determine the speciﬁcity of the
PCR reaction.
2.3. Protein Analysis. An ELISA for VEGF was conducted
according to the manufacturer’s instructions (RayBiotechInternational Journal of Pediatrics 3
Table 1: Primer sequences for mRNA detection of the diﬀerent gene products.
Gen Forward Reverse bp AT
VEGF∗ cca cgt cag aga gca aca tca tca ttc tct cta tgt gct ggc ttt 71 60
SP-B cca cct cct cac aaa gat gac ttg ggg tta atc tgg ctc tgg 174 60
SP-C atg gac atg agt agc aaa gag gt cac gat gag aag gcg ttt gag 119 60
ER-a cgt gtg caa tga cta tgc ctc ttt cat cat gcc cacttcgtaa 199 62
ER-b ctg tga tga act acagtg ttc cc gca gtg ggt ggc taa agg a 124 62
PR cca act tca caa aac ttc tcg aca ggc agc aat aac ttc aga cat ca 127 64
HPRT gct ggt gaa aaggac ctc t cac agg act aga aca cct gc 248 62
∗recognizes transcript variants VEGF 120, 144, and 164.
ELISA Kit, speciﬁc for VEGF-A). For each sample, blank
values(i.e.,thoseforserum-freemedia)weresubtracted,and
mean results were normalized per 105 cells, counted after
trypsination in a Neubauer’s counting chamber. This assay
was performed in triplicate experiments.
2.4. Immunostaining. Purity of cell cultures was determined
by immunohistochemistry for vimentin (ﬁbroblasts, abcam,
Germany, 1:100) and cytokeratin (AT-II cells, abcam, Ger-
many, 1:75). Cells were grown on top of autoclaved 13mm
circular glass cover slips placed in each well of a 24-well
plate. After incubation, the media were aspirated, and cells
were washed twice in PBS. Cells were ﬁxed in methanol and
incubated with 1% BSA and 2% FCS in PBS for 20 minutes
at 23◦C prior to exposure to primary antibodies for 18 hours
at 4◦C. Appropriate secondary antibodies and the AEC Kit
(Zymed Laboratories, Calif, USA) were used for staining.
2.5. Statistical Analysis. Diﬀerences between groups were
tested by one-way analysis of variance (ANOVA) followed
by Tukey’s post hoc multiple range test using SPSS software
(SPSS Inc., Chicago, IL, USA). A P-value of less than .05
was considered signiﬁcant. Results in ﬁgures are presented
as means with standard error of the mean.
3. Results
3.1. Cell Culture Purity and Receptor Expression. The cultur-
ing protocol for lung ﬁbroblast yielded a greater than 98%
homogeneity of vimentin-positive ﬁbroblasts. The culturing
protocol for AT-II cells yielded a greater than 95% homo-
geneity of cytokeratin-positive cells. Cross contamination of
puriﬁed ﬁbroblasts cell cultures was excluded by immuno-
histochemical staining of ﬁbroblast cell cultures with anti-
cytokeratin antibody (Figure 1). No expression of SP-B and
SP-C was detected in lung ﬁbroblasts further proving purity
of cell cultures. Semiquantitative PCR revealed that all three
hormone receptors, namely, estrogen receptor alpha (ER-α),
estrogen receptor beta (ER-β), and the progesterone receptor
(PR)areexpressed in puriﬁed centrallung ﬁbroblastandAT-
II cell cultures (Figure 2).
3.2. Hormonal Eﬀects on Central Lung Fibroblasts. The
treatment of cultured ﬁbroblast with either E2-8M or P-
8M alone for 48 hours had no signiﬁcant inﬂuence on
VEGF mRNA expression (Figure 3). However, a combined
AT-II cells
(a)
Central lung
ﬁbroblasts
(b)
Figure 1: Alevolar cells type II (AT-II) and central lung ﬁbroblasts
stained with cytokeratin antibody. Note that AT-II stain positive for
cytokeratinwhereas ﬁbroblastsdonot.Therefore,contamination of
AT-II cells in ﬁbroblast cell cultures can be excluded.
application with both steroids resulted in a signiﬁcant
increase by approximately 100% compared to controls in
VEGF mRNA levels (P < .01, Figure 3). Dexamethasone was
applied as positive control (P < .01, Figure 3). The combined
application at concentrations lower than 10–8M did not
signiﬁcantly aﬀect VEGF mRNA expression (Figure 4), and
higher concentrations (10–6M) did not further promote
VEGF mRNA expression compared to 10–8M (Figure 4).
The hormone-induced upregulation of VEGF mRNA was
completely blocked by the application of the receptor antag-
onists ICI and RU 486 (Figure 4). The single or combined
treatmentwithICIand/orRU486didnotinﬂuencethebasal
expression of investigated proteins as determined by rt-PCR
analysis (data not shown). Using ELISA analysis, we could4 International Journal of Pediatrics
Fibroblasts 200bp
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AT-II cells 200bp
ERα ERβ PR
(b)
Figure 2: Semiquantitative analysis of estrogen receptor alpha (ER-
α), estrogen receptor beta (ER-β), and the progesterone receptor
(PR) expression in central lung ﬁbroblast and AT-II cell cultures.
Note that all three hormone receptors are expressed in both cell
cultures.
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Figure 3: Quantitative analysis of VEGF gene expression in central
lung ﬁbroblasts treated for 48 hours with E2-8M and P-8M alone
or in combination. Values were normalized against a housekeeping
gene (HPRT) and expressed as % of controls. Note that only the
combined application of both hormones signiﬁcantly increased
VEGF expression in central lung ﬁbroblasts. Also note that the
application of dexamethasone (D) had similar eﬀects on VEGF
expression. ∗P<. 01 control versus E2/P-8M, ∗∗P<. 01 control
versus D-8M.
conﬁrm the transcriptional regulation of VEGF by E2 and P.
Only the combined application increased extracellular VEGF
protein levels in ﬁbroblasts (Figure 5). Pretreatment with the
receptor antagonists again abrogated this eﬀect.
3.3. Hormonal Eﬀects on AT-II cells. As shown for ﬁbroblasts
only the simultaneous exposure to E2-8M and P-8M
signiﬁcantly enhanced the expression of VEGF (Figure 6)
and this could be conﬁrmed at the transcriptional level
(Figure 7). Dexamethasone also increased VEGF amount in
AT-II cells (Figure 6). Combined application of E2 and P
increased mRNA expression of SP-B and SP-C to a similar
extent as dexamethasone (Figure 8). Pretreatment with the
receptor antagonists ICI and RU 468 abrogated this eﬀect.
SP-A was not found in AT-II cells, however was expressed in
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Figure 4: Quantitative analysis of VEGF gene expression in central
lung ﬁbroblasts treated for 48 hours with increasing concentrations
of both E2 and P and with ICI/RU 486. Values were normalized
against a housekeeping gene (HPRT) and expressed as % of
controls. Note that the application of receptor antagonists 1 hour
prior to hormone application (ICI/RU 486) antagonizes hormonal
eﬀects. P<. 01 control versus E2/P-8M; ∗∗P<. 01 control versus
E/P-6M.
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Figure 5:QuantiﬁcationofVEGFproteinreleaseoflungﬁbroblasts
t r e a t e df o r4 8h o u r sw i t hE 2 - 8Ma n dP - 8Ma l o n eo ri nc o m b i n a -
tion determined by ELISA. Note that corresponding with results
obtained by gene expression analysis (Figure 3) VEGF protein is
increased in central lung ﬁbroblast cultures only by combined
treatment with E2 and P. Pretreatment with ICI/RU 486 abrogated
this eﬀect. ∗P<. 05 control versus E2/P-8M.
mature lung tissue which did serve as a positive control (not
shown).
4. Discussion
The role of angiogenic growth factors for developmental
processesisincreasinglyrecognized[25].Adecreasedexpres-
sion may be a potential mechanism of alveolar capillary
dysmorphogenesis in BPD. In animal models of bronchopul-
monary dysplasia and in preterm infants dying from BPD,
diminished VEGF mRNA expression is evident (for a review
see [25]). VEGF stimulates the growth of lung epithelial
cells in vitro [26] and is important for pulmonary vascular
development [27]. Mice with a deﬁciency of VEGF dieInternational Journal of Pediatrics 5
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Figure 6: Quantitative analysis of VEGF gene expression in
alveolar cells type II treated for 48 hours with E2-8M and P-
8M alone or in combination. Values were normalized against a
housekeeping gene (HPRT) and expressed as % of controls. Note
that only the combined application of both hormones signiﬁcantly
increased VEGF expression in central lung ﬁbroblasts. Also note
that the application on dexamethasone had similar eﬀects on VEGF
expression. ∗P<. 01 control versus E2/P-8M, ∗∗P<. 01 control
versus D-8M.
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Figure 7: Quantiﬁcation of VEGF protein release of alveolar
cells type II treated for 48h with E2-8M and P-8M alone or
in combination determined by ELISA. Note that corresponding
with results obtained by gene expression analysis (Figure 6)V E G F
protein is increased in alveolar type II cell cultures only by
combined treatment with E2 and P. Pretreatment with ICI/RU 486
abrogated this eﬀect. ∗P<. 05 control versus E2/P-8M.
from RDS [17], and VEGF knockout results in embryonic
lethality [15]. To our knowledge no data on the inﬂuence
of E2 and P on VEGF expression in the developing lung is
available. In primary lung ﬁbroblasts and AT-II cells only
the combined application of E2 and P resulted in increased
expression levels of VEGF mRNA and VEGF protein. This
eﬀect was abolished by pretreatment with the speciﬁc E2 and
P antagonists ICI and RU 486, respectively. Assuming that
E2 and P increase VEGF expression in the developing lung in
vivo, the withdrawal of the placental supply of E2 and P in
preterm infants may explain the disturbed lung development
and function. Postnatal replacement of E2 and P in preterm
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Figure 8: Quantitative analysis of SP-B and SP-C gene expression
in alveolar cells type II treated for 48 hours with E2-8M/P-
8M in combination or with dexamethasone-8M. Values were
normalized against a housekeeping gene (HPRT) and expressed as
% of controls. Note that combined hormonal treatment increased
expression of both surfactant proteins to a similar extent like
dexamethasone. Further note that pretreatment with the receptor
antagonists ICI and RU 486 antagonized the hormonal eﬀects. ∗P<
.01 control versus E2/P-8M; ∗∗P<. 01 control versus D-8M.
infants was associated with a trend toward reduced incidence
of BPD [5, 7].
Disturbed lung function in RDS of preterm infants is due
to surfactant deﬁciency. A regulative role of E2 in surfactant
synthesisissupportedbyenhancedmRNAexpressionforSP-
B found in fetal rabbit lung cells [28]. Our data supports a
regulative role of E2 and P for surfactant synthesis as in AT-II
cells combined treatment with E2 and P resulted not only in
increased VEGF but also in increased mRNA expression of
SP-B and SP-C. We did not perform experiments to evaluate
the role of VEGF for surfactant synthesis. However, data
from the literature implicates a trigger function of VEGF
for surfactant synthesis. Intra-amniotic injection of VEGF
in preterm rats resulted in increased SP-B mRNA expression6 International Journal of Pediatrics
[18]. Furthermore, type II pneumocytes respond to VEGF
by enhancing their expression of SP-B and SP-C [17]. We
speculate that E2 and P promote VEGF production and,
thereby, surfactant synthesis.
One major ﬁnding of our study is that only the com-
bination of E2 and P was eﬀective in the upregulation of
VEGF, SP-B, and SP-C expression. This is in accordance
with ﬁndings about the epithelial Na+-channel which plays
a critical role in the active reabsorption of alveolar ﬂuid at
the time of birth and during pulmonary oedema. In rats,
only the combined application of E2 and P promoted mRNA
levels of the epithelial Na+-channel in the lung suggesting
complex interactions between the intracellular E2 and P
signalling [29]. It appeared that only the administration of
both hormones is fully eﬀective in preventing demyelination
in a multiple sclerosis animal model [30]. It is well known
that ER and PR are coexpressed in the same cells in several
areas of the target tissues [31, 32]. In addition, a number of
reports demonstrated that ER and PR can have synergistic
or inhibitory cross-talk in their transcriptional regulation
in promoter type- and PR subtype-speciﬁc manners [33,
34]. Also interactions on well-known nongenomic levels
are assumed. For example, in breast cancer cells, estrogens
activate the Src/Erk pathway through an interaction of
the ER with the SH2 domain of c-Src. Progestins have
been reported to activate also this pathway either via an
interaction of the PR with ER, which itself activates c-
Src, or by direct interaction of PR with the SH3 domain
of c-Src [35]. Future studies have to show the underlying
mechanisms for combined positive hormonal eﬀects. The
preterm infant is deprived of both E2 and P, simultaneously.
Our study adds evidence that only combined replacement of
E2 and P may be eﬀective to prevent BPD in preterm infants
[5, 7].
Treatment with dexamethasone increased VEGF mRNA
expression and VEGF protein in lung ﬁbroblasts and AT-
II cells. In contrast, in vitro studies have shown that dex-
amethasone downregulates VEGF expression in cells derived
from alveolar epithelial cells [36]. However, in mid-trimester
fetal human lung explants dexamethasone increased VEGF
mRNA expression [37] and this at least at the translational
level was also found in vivo [38]. Interestingly, treatment
of preterm infants with dexamethasone was associated with
increased VEGF levels in deep pulmonary lavages [39].
The embryos were not stratiﬁed by gender. Therefore,
we cannot exclude that by chance some experiments were
conducted in cell cultures from predominant male or
female embryos. The steroid concentrations being most
eﬀective in our experiments, that is, 10–8M, appear at
ﬁrst glance to be above the physiological plasma levels
found in rodents during the estrous cycle. However, it is
generally accepted that under in vitro conditions higher
steroid levels are required to yield cellular eﬀects. In previous
in vitro studies, these high estrogen concentrations were
applied to generate physiological eﬀects [40, 41]. Another
more intriguing point is that tissues themselves produce
steroids. Thus, tissue intrinsically synthesized steroids may
contributetogetherwithplasmasteroidstoreachhigherlocal
tissue steroid concentrations. In support for this view is the
recent observation that in rodent hippocampal tissue local
estrogen production yields tissue steroid levels at approxi-
mately 10–9M which are greater than those in the plasma
[42].
In conclusion, combined use of E2 and P enhanced
expression of VEGF and surfactant proteins in primary
embryonic lung cells. These proteins are known to be key
factors for the prenatal lung development and postnatal lung
function. Further research about the eﬀects of E2 and P
on lung development may open therapeutic perspectives for
preterm infant prone to develop lung disease.
Abbreviations and Conversion Factors
AT-II: Alveolar cells type II
BPD: Bronchopulmonary dysplasia
D: Dexamethasone
E2: 17β-Estradiol, pg/mL × 3.671 = pmol/L
ER-α: Estrogen receptor alpha
ER-β: Estrogen receptor beta
ICI:
ICI 182.780 = 7α-[9-[(4,4,5,5,5-
Pentaﬂuoropentyl)sulphinyl] nonyl]
-estra-1,3,5(10)-triene-3,17 β-diol
M: Molar
MEM: Minimum essential medium
Mrna: Messenger ribonucleic acid
P: Progesterone, ng/mL × 3.18 = nmol/l
PR: Progesterone receptor
RDS: Respiratory distress syndrome
RU 486: Mifepristone
SP-B: Surfactant protein B
SP-C: Surfactant protein C
VEGF: Vascular endothelial growth factor A
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